591 related articles for article (PubMed ID: 30576610)
1. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.
Dubash S; Bridgewood C; McGonagle D; Marzo-Ortega H
Expert Rev Clin Immunol; 2019 Feb; 15(2):123-134. PubMed ID: 30576610
[TBL] [Abstract][Full Text] [Related]
2. IL-17 inhibition in axial spondyloarthritis: current and future perspectives.
Torgutalp M; Poddubnyy D
Expert Opin Biol Ther; 2019 Jul; 19(7):631-641. PubMed ID: 30957574
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis.
Wendling D; Verhoeven F; Prati C
Expert Opin Biol Ther; 2019 Jan; 19(1):55-64. PubMed ID: 30500270
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab (AIN457) in the treatment of ankylosing spondylitis.
Braun J; Baraliakos X; Kiltz U
Expert Opin Biol Ther; 2016; 16(5):711-22. PubMed ID: 26982813
[TBL] [Abstract][Full Text] [Related]
5. Ixekizumab for treating ankylosing spondylitis.
Kiwalkar S; Beier S; Deodhar A
Immunotherapy; 2019 Oct; 11(15):1273-1282. PubMed ID: 31530049
[TBL] [Abstract][Full Text] [Related]
6. Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis.
Harrison SR; Marzo-Ortega H
Expert Rev Clin Immunol; 2021 Oct; 17(10):1059-1071. PubMed ID: 34407705
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis.
Katsevman GA; Mariscal G; Barrios C; Domenech-Fernández P; Ziembinski C; Bhatia S
Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):160-166. PubMed ID: 33001775
[TBL] [Abstract][Full Text] [Related]
8. Safety of secukinumab for the treatment of active ankylosing spondylitis.
Loricera J; Galíndez-Aguirregoikoa E; Blanco R
Expert Opin Drug Saf; 2021 Jun; 20(6):627-634. PubMed ID: 33470130
[No Abstract] [Full Text] [Related]
9. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
[TBL] [Abstract][Full Text] [Related]
10. Targeting the interleukin-23/17 axis in axial spondyloarthritis.
Paine A; Ritchlin CT
Curr Opin Rheumatol; 2016 Jul; 28(4):359-67. PubMed ID: 27152702
[TBL] [Abstract][Full Text] [Related]
11. New treatment targets for axial spondyloarthritis.
Sieper J
Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii38-ii42. PubMed ID: 27856659
[TBL] [Abstract][Full Text] [Related]
12. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
Front Immunol; 2020; 11():1894. PubMed ID: 32973785
[TBL] [Abstract][Full Text] [Related]
13. Effect of IL-17A blockade with secukinumab in autoimmune diseases.
Patel DD; Lee DM; Kolbinger F; Antoni C
Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii116-23. PubMed ID: 23253932
[TBL] [Abstract][Full Text] [Related]
14. IL-17 for therapy.
Kurschus FC; Moos S
J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
[TBL] [Abstract][Full Text] [Related]
15. IL-17 Blockade in Psoriasis.
Burkett PR; Kuchroo VK
Cell; 2016 Dec; 167(7):1669. PubMed ID: 27984714
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland.
Mørup MF; Taieb V; Willems D; Rose M; Lyris N; Lamotte M; Gerlier L; Thom H
J Med Econ; 2024; 27(1):682-696. PubMed ID: 38650583
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL17 therapies for psoriasis.
Silfvast-Kaiser A; Paek SY; Menter A
Expert Opin Biol Ther; 2019 Jan; 19(1):45-54. PubMed ID: 30500317
[TBL] [Abstract][Full Text] [Related]
18. Anti-interleukin-17 treatment of psoriasis.
Jinna S; Strober B
J Dermatolog Treat; 2016 Aug; 27(4):311-5. PubMed ID: 26943806
[TBL] [Abstract][Full Text] [Related]
19. The role of secukinumab in the treatment of ankylosing spondylitis.
Shah R; Perry L; Deodhar A
Immunotherapy; 2015; 7(12):1241-7. PubMed ID: 26595091
[TBL] [Abstract][Full Text] [Related]
20. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]